• No results found

[PDF] Top 20 Impact of tandem autologous stem cell transplantation and response to transplant in the outcome of multiple myeloma

Has 10000 "Impact of tandem autologous stem cell transplantation and response to transplant in the outcome of multiple myeloma" found on our website. Below are the top 20 most common "Impact of tandem autologous stem cell transplantation and response to transplant in the outcome of multiple myeloma".

Impact of tandem autologous stem cell transplantation and response to transplant in the outcome of multiple myeloma

Impact of tandem autologous stem cell transplantation and response to transplant in the outcome of multiple myeloma

... with autologous stem cell rescue as consolidation after induc- tion chemotherapy (QT), improving the progression-free survival and overall survival of MM patients when com- pared to regimens ... See full document

7

Flow cytometry remission by Ig light chains ratio is a powerful marker of outcome in multiple myeloma after tandem autologous transplant: a real-life study

Flow cytometry remission by Ig light chains ratio is a powerful marker of outcome in multiple myeloma after tandem autologous transplant: a real-life study

... and outcome prediction in hematological malignancies and several reports are focusing on its clinical relevance in multiple myeloma (MM) patients [1–9], in order to better subcategorize the quality ... See full document

8

The Impact of Pretransplant Disease Characteristics on the Outcome of Autologous Stem Cell Transplantation for Neuroblastoma with High Risk Features: A Retrospective Model from a Limited Resources Country

The Impact of Pretransplant Disease Characteristics on the Outcome of Autologous Stem Cell Transplantation for Neuroblastoma with High Risk Features: A Retrospective Model from a Limited Resources Country

... survival outcome. Improvement of outcome is attributed to the consolidation of chemotherapy by autologous bone marrow ...the outcome by tandem autologous transplant is ... See full document

11

Role of autologous and allogeneic stem cell transplantation in myeloma.

Role of autologous and allogeneic stem cell transplantation in myeloma.

... the tandem auto group compared to 11% for the auto-allo ...complete response and very good PR rates were 51% and 62% respectively for the tandem auto and auto-allo ...the tandem auto and ... See full document

24

Patient-Reported Outcome Results From the Open-Label, Randomized Phase III Myeloma X Trial Evaluating Salvage Autologous Stem-Cell Transplantation in Relapsed Multiple Myeloma

Patient-Reported Outcome Results From the Open-Label, Randomized Phase III Myeloma X Trial Evaluating Salvage Autologous Stem-Cell Transplantation in Relapsed Multiple Myeloma

... sASCT was expected to be superior to NTC in terms of TTP. Therefore, ASCT-related toxicity in the short term and its potential impact on QoL, as well as patients ’ long-term QoL, were of interest. EORTC QLQ-C30, ... See full document

13

IgD multiple myeloma a descriptive report of 17 cases: survival and response to therapy

IgD multiple myeloma a descriptive report of 17 cases: survival and response to therapy

... with autologous stem cell transplantation (HDT/ASCT), five single and six tandem ASCT: six received bortezomib and/or thalidomide as induction therapy and five ...overall ... See full document

5

Comparative efficacy of tandem autologous versus autologous followed by allogeneic hematopoietic cell transplantation in patients with newly diagnosed multiple myeloma: a systematic review and meta-analysis of randomized controlled trials

Comparative efficacy of tandem autologous versus autologous followed by allogeneic hematopoietic cell transplantation in patients with newly diagnosed multiple myeloma: a systematic review and meta-analysis of randomized controlled trials

... of response outcomes, sensitivity analysis was performed according to response criteria (EBMT [21], IUR [22], non-EBMT/IUR [15], and not ...primary outcome of OS was performed according to all ... See full document

12

Patient-reported outcome results from the open-label, randomized phase III myeloma X trial evaluating salvage autologous stem-cell transplantation in relapsed multiple myeloma

Patient-reported outcome results from the open-label, randomized phase III myeloma X trial evaluating salvage autologous stem-cell transplantation in relapsed multiple myeloma

... sASCT was expected to be superior to NTC in terms of TTP. Therefore, ASCT-related toxicity in the short term and its potential impact on QoL, as well as patients’ long-term QoL, were of interest. EORTC QLQ-C30, ... See full document

14

FIFTEEN YEARS OF SINGLE CENTER EXPERIENCE WITH STEM CELL TRANSPLANTATION FOR MULTIPLE MYELOMA: A RETROSPECTIVE ANALYSIS

FIFTEEN YEARS OF SINGLE CENTER EXPERIENCE WITH STEM CELL TRANSPLANTATION FOR MULTIPLE MYELOMA: A RETROSPECTIVE ANALYSIS

... Introduction: Autologous stem cell transplantation (AsCt) became standard of care for patients with multi- ple myeloma (MM) under the age of 65 ...of transplant. We observed ... See full document

5

Original Article Bortezomib in combination with chemotherapy and autologous hematopoietic stem cell transplantation in the treatment of newly diagnosed multiple myeloma patients: single-center study results

Original Article Bortezomib in combination with chemotherapy and autologous hematopoietic stem cell transplantation in the treatment of newly diagnosed multiple myeloma patients: single-center study results

... for transplant is expected to reduce malignant plasma cells load and increase remission depth ...each Myeloma Cooperative Group who has worldwide reputation has made differ- ent treatment strategies to ... See full document

8

Tackling mantle cell lymphoma (MCL): Potential benefit of allogeneic stem cell transplantation

Tackling mantle cell lymphoma (MCL): Potential benefit of allogeneic stem cell transplantation

... requiring stem cell support. Autologous SCT is currently a favored approach as consoli- dation of first remission or, if not utilized until that point, as part of therapy for first relapse in ... See full document

10

A serum microRNA signature associated with complete remission and progression after autologous stem-cell transplantation in patients with multiple myeloma

A serum microRNA signature associated with complete remission and progression after autologous stem-cell transplantation in patients with multiple myeloma

... for stem-cell ...prognostic impact of the serum expression of miR-16 and miR-25 at diagnosis, together with cytogenetics by FISH and ISS, which were already well established as prognostic factors, ... See full document

10

Darbepoietin Alfa after High Dose Melphalan and Autologous Hemopoietic Progenitor Cell in Multiple Myeloma Patients: A Pilot Study

Darbepoietin Alfa after High Dose Melphalan and Autologous Hemopoietic Progenitor Cell in Multiple Myeloma Patients: A Pilot Study

... after transplant when the autologous marrow is recovering and, therefore, much more likely to respond to the exogenous Epo ...of response, where the patients with Epo levels less than 50 have the ... See full document

7

Different role of circulating myeloid-derived suppressor cells in patients with multiple myeloma undergoing autologous stem cell transplantation

Different role of circulating myeloid-derived suppressor cells in patients with multiple myeloma undergoing autologous stem cell transplantation

... Despite the advent of novel agents and doubling of survival rates, MM is still considered an incurable malig- nancy [43], and ASCT is still the first-line treatment for transplant eligible patients [44]. MM is ... See full document

13

Evaluation of a biosimilar granulocyte colony-stimulating factor (filgrastim XM02) for peripheral blood stem cell mobilization and transplantation: a single center experience in Japan

Evaluation of a biosimilar granulocyte colony-stimulating factor (filgrastim XM02) for peripheral blood stem cell mobilization and transplantation: a single center experience in Japan

... blood stem cell mobilization strategy in autologous hematopoieitic stem cell transplantation: a single center experience from ...blood stem cell mobi- lization: an ... See full document

8

Successful Outcome of Autologous Stem Cell Transplantation for Relapsed or Refractory Germ Cell Tumors

Successful Outcome of Autologous Stem Cell Transplantation for Relapsed or Refractory Germ Cell Tumors

... with autologous stem cell transplantation (HDCT-ASCT) have been utilized 8 ...increases response rates and survival but with significant morbidity and treatment-related mortality ... See full document

5

Autologous Haematopoietic Stem Cell Transplantation in Multiple Sclerosis: a Review of Current Literature and Future Directions for Transplant Haematologists and Oncologists.

Autologous Haematopoietic Stem Cell Transplantation in Multiple Sclerosis: a Review of Current Literature and Future Directions for Transplant Haematologists and Oncologists.

... Marrow Transplant Research (CIBMTR) registries revealed that the TRM was associated with the experience of the treatment centre [9, ...a transplant centre, the care service is usually tai- lored for ... See full document

10

Effect of remission status and induction chemotherapy regimen on outcome of autologous stem cell transplantation for mantle cell lymphoma.

Effect of remission status and induction chemotherapy regimen on outcome of autologous stem cell transplantation for mantle cell lymphoma.

... transplantation (ASCT) has become an increasingly common treatment for MCL. Initally, ASCT was reserved as salvage therapy for relapsed or refractory disease, but outcomes were poor with this strategy [4,5]. In ... See full document

33

Case Report Successful treatment with autologous peripheral blood stem cell transplantation for multiple myeloma concurrent systemic lupus erythematosus: a case report

Case Report Successful treatment with autologous peripheral blood stem cell transplantation for multiple myeloma concurrent systemic lupus erythematosus: a case report

... IgG/λ. Autologous antibodies tests showed positive autoantibody to nuclear antigen (ANA) with the titer of 1:320, as well as positive anti-ribonu- cleoprotein antibody, anti-Smith antibody and anti SS-A ...IgG/λ. ... See full document

5

Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma

Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma

... a myeloma-propagating phenotype (44, ...embryonic stem cells ...cancer stem cells) (59, ...in myeloma-propagating phenotypes in vitro (44, ...symptomatic multiple myeloma but are ... See full document

15

Show all 10000 documents...